MVP 2.17% 45.0¢ medical developments international limited

I agree. The lack of communication is concerning. Are they not...

  1. 3,866 Posts.
    lightbulb Created with Sketch. 1319
    I agree. The lack of communication is concerning.
    Are they not reporting progress or is no progress being made?
    Either way, I don't like it.

    The document linked below was published last week.
    The decision itself is dated 13/3/23.

    It states in the document:
    "Date of completion of the paediatric investigation plan: By December 2023"

    P/0080/2023 : EMA decision of 13 March 2023 on the acceptance of a modification of an agreed paediatric investigation plan for methoxyflurane (Penthrox and associated names) (EMEA-000334-PIP01-08-M11)
    First published:
    05/04/2024
    https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000334-pip01-08-m11

    I'm wondering if this indicates that the MAGPIE trial has been completed.

    MEOF-002 - Methoxyflurane AnalGesia for Paediatric InjuriEs (MAGPIE)
    https://clinicaltrials.gov/study/NCT03215056
    https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004290-41/GB
 
watchlist Created with Sketch. Add MVP (ASX) to my watchlist
(20min delay)
Last
45.0¢
Change
-0.010(2.17%)
Mkt cap ! $38.83M
Open High Low Value Volume
46.0¢ 46.0¢ 42.0¢ $175.7K 404.3K

Buyers (Bids)

No. Vol. Price($)
1 13239 45.0¢
 

Sellers (Offers)

Price($) Vol. No.
47.0¢ 910 1
View Market Depth
Last trade - 16.10pm 02/05/2024 (20 minute delay) ?
Last
45.0¢
  Change
-0.010 ( 3.23 %)
Open High Low Volume
45.0¢ 48.0¢ 41.5¢ 35352
Last updated 15.59pm 02/05/2024 ?
MVP (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.